Postantifungal effect of anidulafungin against Candida albicans, Candida dubliniensis, Candida africana, Candida parapsilosis, Candida metapsilosis and Candida orthopsilosis.


Journal

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia
ISSN: 1988-9518
Titre abrégé: Rev Esp Quimioter
Pays: Spain
ID NLM: 9108821

Informations de publication

Date de publication:
Apr 2019
Historique:
pubmed: 9 3 2019
medline: 20 8 2019
entrez: 9 3 2019
Statut: ppublish

Résumé

Candida albicans remains the most common aetiology of invasive candidiasis, leading to high morbidity and mortality. Nevertheless, the incidence of candidiasis due to non-C. albicans species, such as Candida parapsilosis, is increasing. Postantifungal effect (PAFE) is relevant for establishing dosage schedules in antifungal therapy, as the frequency of antifungal administration could change depending on PAFE. The aim of this study was to evaluate the PAFE of anidulafungin against C. albicans, Candida dubliniensis, Candida africana, C. parapsilosis, Candida metapsilosis and Candida orthopsilosis. Twenty-one Candida strains were evaluated. Cells were exposed to anidulafungin for 1 h at concentrations ranging from 0.12 to 8 mg/L for PAFE studies. Time-kill experiments (TK) were conducted at the same concentrations. The experiments were performed using an inoculum of 1-5 x 105 cells/mL and 48 h incubation. Readings of PAFE and TK were done at 0, 2, 4, 6, 24 and 48 h. Anidulafungin was fungicidal against 2 out of 14 (14%) strains of C. albicans related species in PAFE experiments. Moreover, 2 mg/L of anidulafungin exerted a prolonged PAFE (≥ 33.6 h) against 13 out of 14 (93%) strains. Similarly, fungicidal endpoint was achieved against 1 out of 7 (14%) strains of C. parapsilosis complex, being PAFE prolonged (≥ 42 h) against 6 out of 7 (86%) strains. Anidulafungin induced a significant and prolonged PAFE against C. albicans and C. parapsilosis and their related species.

Identifiants

pubmed: 30847462
pii: gil08mar2019
pmc: PMC6441987
pii:

Substances chimiques

Antifungal Agents 0
Anidulafungin 9HLM53094I

Types de publication

Journal Article

Langues

eng

Pagination

183-188

Informations de copyright

©The Author 2019. Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).

Références

Antimicrob Agents Chemother. 2000 Apr;44(4):1108-11
pubmed: 10722525
Antimicrob Agents Chemother. 2006 Jul;50(7):2569-72
pubmed: 16801448
J Clin Microbiol. 2008 Aug;46(8):2659-64
pubmed: 18562582
Antimicrob Agents Chemother. 2009 Aug;53(8):3347-52
pubmed: 19364856
Antimicrob Agents Chemother. 2010 May;54(5):2194-7
pubmed: 20145083
Diagn Microbiol Infect Dis. 2010 Nov;68(3):278-83
pubmed: 20846808
J Antimicrob Chemother. 2011 Oct;66(10):2315-22
pubmed: 21795259
Diagn Microbiol Infect Dis. 2011 Oct;71(2):131-8
pubmed: 21865002
J Antimicrob Chemother. 2012 May;67(5):1181-7
pubmed: 22351683
Med Mycol. 2013 Jan;51(1):60-5
pubmed: 22746405
Rev Iberoam Micol. 2014 Jan-Mar;31(1):42-8
pubmed: 24270071
Antimicrob Agents Chemother. 2014;58(2):916-22
pubmed: 24277027
Cold Spring Harb Perspect Med. 2014 Nov 10;5(5):a019653
pubmed: 25384765
Diagn Microbiol Infect Dis. 2015 May;82(1):57-61
pubmed: 25703894
PLoS One. 2015 Jul 13;10(7):e0132730
pubmed: 26168269
Diagn Microbiol Infect Dis. 2016 Oct;86(2):172-7
pubmed: 27492134
J Clin Microbiol. 2018 Mar 26;56(4):
pubmed: 29212705
J Mycol Med. 2018 Mar;28(1):51-58
pubmed: 29366545

Auteurs

N Jauregizar (N)

Nerea Jauregizar, Department of Pharmacology (Unidad de formación e investigación multidisciplinar «Microbios, y Salud»), Faculty of Medicine and Nursing, University of Basque Country (UPV/EHU), Bilbao, Spain. nerea.jauregizar@ehu.eus.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH